Nothing Special   »   [go: up one dir, main page]

ES2193337T3 - Utilizacion de sales de estroncio para el tratamiento de la artrosis. - Google Patents

Utilizacion de sales de estroncio para el tratamiento de la artrosis.

Info

Publication number
ES2193337T3
ES2193337T3 ES97401362T ES97401362T ES2193337T3 ES 2193337 T3 ES2193337 T3 ES 2193337T3 ES 97401362 T ES97401362 T ES 97401362T ES 97401362 T ES97401362 T ES 97401362T ES 2193337 T3 ES2193337 T3 ES 2193337T3
Authority
ES
Spain
Prior art keywords
treatment
artrosis
strontium salts
strontium
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97401362T
Other languages
English (en)
Inventor
Yannis Tsouderos
Pascale Deloffre
Michel Wierzbicki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Application granted granted Critical
Publication of ES2193337T3 publication Critical patent/ES2193337T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA INVENCION SE REFIERE A LA UTILIZACION DE SALES DE ESTRONCIO PARA LA OBTENCION DE COMPOSICIONES FARMACEUTICAS DESTINADAS A LA PREVENCION Y AL TRATAMIENTO DE LA ARTROSIS.
ES97401362T 1996-06-17 1997-06-16 Utilizacion de sales de estroncio para el tratamiento de la artrosis. Expired - Lifetime ES2193337T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9607475A FR2749759B1 (fr) 1996-06-17 1996-06-17 Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose

Publications (1)

Publication Number Publication Date
ES2193337T3 true ES2193337T3 (es) 2003-11-01

Family

ID=9493102

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97401362T Expired - Lifetime ES2193337T3 (es) 1996-06-17 1997-06-16 Utilizacion de sales de estroncio para el tratamiento de la artrosis.

Country Status (16)

Country Link
US (1) US5856356A (es)
EP (1) EP0813869B1 (es)
JP (1) JP3935557B2 (es)
CN (1) CN1136856C (es)
AT (1) ATE233558T1 (es)
AU (1) AU711950B2 (es)
BR (1) BR9703603A (es)
CA (1) CA2206837C (es)
DE (1) DE69719408T2 (es)
DK (1) DK0813869T3 (es)
ES (1) ES2193337T3 (es)
FR (1) FR2749759B1 (es)
HU (1) HU227935B1 (es)
NO (1) NO315840B1 (es)
NZ (1) NZ328106A (es)
ZA (1) ZA975323B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8303981B2 (en) 1996-08-27 2012-11-06 Baxter International Inc. Fragmented polymeric compositions and methods for their use
FR2828206B1 (fr) * 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
NO20014746D0 (no) * 2001-09-28 2001-09-28 Clas M Kjoelberg Smertelindrende middel
FR2844795B1 (fr) * 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates
FR2844797B1 (fr) 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2846558B1 (fr) * 2002-11-05 2006-07-14 Servier Lab Utilisation du sel distrontique de l'acide 2-n,n-di(carboxymethyl)amino-3-cyano-4-carboxymethyl- thiophene-5-carboxylique pour l'obtention de medicaments destines au traitement des douleurs gastro-duodenales
EP1605955B1 (en) * 2003-03-27 2015-08-19 SantoSolve AS Anti-inflammatory composition based on strontium compounds
ATE342722T1 (de) * 2003-05-07 2006-11-15 Osteologix As Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
PT1622630E (pt) * 2003-05-07 2012-10-11 Osteologix As Combinações de estrôncio para a profilaxia/tratamento de patologias da cartilagem e/ou do osso
JP5049589B2 (ja) * 2003-05-07 2012-10-17 オステオロジックス エイ／エス ストロンチウム塩含有の放出制御組成物
US7927626B2 (en) 2003-08-07 2011-04-19 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
AU2005216596B2 (en) * 2004-02-26 2011-03-24 Osteologix A/S Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
WO2005108339A2 (en) * 2004-05-06 2005-11-17 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
US20090035315A1 (en) * 2004-06-17 2009-02-05 Stephan Christgau Method of Improving Treatments in Rheumatic and Arthritic Diseases
EP1758652A2 (en) * 2004-06-17 2007-03-07 Osteologix A/S Improving pain treatment with strontium combinations
US7618651B2 (en) * 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
CA2571449C (en) * 2004-06-25 2015-12-08 John Nikolaj Hvarre Christensen Compositions comprising strontium and vitamin d and uses thereof
CN101018586B (zh) * 2004-06-25 2014-08-27 莫克瓦洛Spf有限公司 含锶和维生素d的组合物及其用途
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
HUE028342T2 (en) 2004-10-08 2016-12-28 Forward Pharma As Pharmaceutical preparations containing controlled release fumaric acid ester
US20080004344A1 (en) * 2004-11-10 2008-01-03 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
EP1855654A1 (en) * 2005-02-28 2007-11-21 Osteologix A/S Tablets comprising a high load of strontium
FR2899895B1 (fr) * 2006-04-12 2010-09-17 Servier Lab Nouveaux sels de strontium d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2007268175B2 (en) * 2006-05-26 2013-05-23 Baxter Healthcare S.A. Injectable fibrin composition for bone augmentation
GB0612028D0 (en) * 2006-06-16 2006-07-26 Imp Innovations Ltd Bioactive glass
US20070292535A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating arthritic and or osteoporitic conditions
US20070292529A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating osteoporotic conditions
CN101204375B (zh) * 2006-12-19 2010-09-29 北京德众万全药物技术开发有限公司 一种雷奈酸锶干混悬剂
ES2573327T3 (es) * 2007-04-23 2016-06-07 Baxter International Inc. Composiciones de fibrina que contienen compuestos de estroncio
GB0713094D0 (en) * 2007-07-05 2007-08-15 Imp Innovations Ltd Glass polycarboxylate cements
GB0724556D0 (en) * 2007-12-17 2008-01-30 Queen Mary & Westfield College LAtency associated protein construct with aggrecanase sensitive cleavage site
WO2009109194A2 (en) 2008-02-29 2009-09-11 Ferrosan A/S Device for promotion of hemostasis and/or wound healing
GB0809592D0 (en) * 2008-05-27 2008-07-02 Imp Innovations Ltd Biomaterials
EP2293738A2 (en) * 2008-05-27 2011-03-16 Imperial Innovations Limited Process for producing porous scaffolds from sinterable glass
EP3090733A1 (en) 2009-01-09 2016-11-09 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
GB0911365D0 (en) 2009-06-30 2009-08-12 Bioceramic Therapeutics Ltd Multicomponent glasses for use as coatings and in personal care products
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
WO2011110597A1 (de) 2010-03-11 2011-09-15 Azad Pharmaceutical Ingredients Ag Verfahren zur herstellung von strontiumranelat
SA111320355B1 (ar) 2010-04-07 2015-01-08 Baxter Heathcare S A إسفنجة لايقاف النزف
CN103037845B (zh) 2010-06-01 2015-11-25 巴克斯特国际公司 用于制备干燥、稳定的止血组合物的方法
EP2530068A1 (en) 2011-05-31 2012-12-05 Lacer, S.A. New strontium salts, synthesis and use thereof in the treatment of osteoporosis
EP4137164A1 (en) 2011-10-11 2023-02-22 Baxter International Inc. Hemostatic compositions
EP4137165A1 (en) 2011-10-11 2023-02-22 Baxter International Inc. Hemostatic compositions
SA112330957B1 (ar) 2011-10-27 2015-08-09 باكستر انترناشونال انك. تركيبات لإيقاف النزف
RU2657955C2 (ru) 2012-03-06 2018-06-18 Ферросан Медикал Дивайсиз А/С Контейнер под давлением, содержащий гемостатическую пасту
CN104349797B (zh) 2012-06-12 2017-10-27 弗罗桑医疗设备公司 干止血组合物
AU2014283170B2 (en) 2013-06-21 2017-11-02 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
JP6489485B2 (ja) 2013-12-11 2019-03-27 フェロサン メディカル デバイシーズ エイ／エス 押し出し増強因子を含んでいる乾燥組成物
JP6726852B2 (ja) 2014-10-13 2020-07-22 フェッローサン メディカル ディバイス エー／エス 止血および創傷治癒に使用するための乾燥組成物
US10653837B2 (en) 2014-12-24 2020-05-19 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
WO2017005590A1 (en) 2015-07-03 2017-01-12 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
WO2018084959A2 (en) 2016-09-30 2018-05-11 Nelson Deanna J Pharmaceutical quality strontium l-lactate
ES2968412T3 (es) 2018-05-09 2024-05-09 Ferrosan Medical Devices As Método para preparar una composición hemostática

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152431A (en) * 1977-09-22 1979-05-01 William H. Rorer, Inc. Compositions and method of use
FR2633619B1 (fr) * 1988-06-29 1991-02-08 Adir Nouveau sel de strontium, son procede de preparation et les compositions pharmaceutiques le renfermant
FR2651497B1 (fr) * 1989-09-01 1991-10-25 Adir Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.

Also Published As

Publication number Publication date
DE69719408D1 (de) 2003-04-10
NO972764L (no) 1997-12-18
EP0813869A1 (fr) 1997-12-29
ZA975323B (en) 1998-01-14
HU227935B1 (en) 2012-06-28
AU2490297A (en) 1998-01-08
FR2749759B1 (fr) 1999-11-26
CA2206837A1 (fr) 1997-12-17
ATE233558T1 (de) 2003-03-15
HU9701059D0 (en) 1997-08-28
CA2206837C (fr) 2002-12-03
BR9703603A (pt) 1998-09-01
FR2749759A1 (fr) 1997-12-19
US5856356A (en) 1999-01-05
JPH1059852A (ja) 1998-03-03
DK0813869T3 (da) 2003-06-02
JP3935557B2 (ja) 2007-06-27
NO315840B1 (no) 2003-11-03
HUP9701059A2 (hu) 1998-03-02
HUP9701059A3 (en) 1998-05-28
NO972764D0 (no) 1997-06-16
CN1179944A (zh) 1998-04-29
AU711950B2 (en) 1999-10-28
NZ328106A (en) 2001-04-27
EP0813869B1 (fr) 2003-03-05
DE69719408T2 (de) 2003-12-24
CN1136856C (zh) 2004-02-04

Similar Documents

Publication Publication Date Title
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
PT1235799E (pt) Forma polimorfica de atorvastatina-calcio
BR9713363A (pt) Epotilonas c, d, e e f, preparação e composições
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
PT1193270E (pt) Pirrolobenzodiazepinas
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
CY1105125T1 (el) Χρηση αναστολεων ακετυλοχολινεστepασης για την παρασκευη φαρμακευτικων συνθεσεων για τη θepαπευτικη αντιμετωπιση συνδρομων λειτουργικων και/ή οργανικων πονων
UY25157A1 (es) Composiciones farmacéuticas conteniendo atorvastatina y amlodipino
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
PA8484301A1 (es) Formulaciones farmaceuticas de liberacion controlada
BR9805544A (pt) Uso de um composto.
ES2194107T3 (es) Formulaciones farmaceuticas y dieteticas para la profilaxis y tratamiento de trastornos gastrointestinales.
SE9802208D0 (sv) Novel compounds
HUP0100539A2 (hu) D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására
EA200401183A1 (ru) Применение ингибиторов il-18 в качестве диагностического маркера
ES2192704T3 (es) Innovadoras composiciones farmaceuticas.
SE9901077D0 (sv) Novel use
ES2170143T3 (es) Composiciones que comprenden halofantrina en una forma especial.
SE9801494D0 (sv) Novel use
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
DE69819539D1 (de) Antithrombotische mittel
BR9806083A (pt) Composi-Æo farmac-utica para o tratamento da hapattite c
SE9802209D0 (sv) Novel compounds
AR025379A1 (es) 9a-azalidas con actividad antibacteriana.